TCM AI and overseas travel go hand in hand! Gushengtang (02273) “Technology+Globalization” Unleashes New Growth Momentum
The Zhitong Finance App learned that on December 5, 2025, Gushengtang (02273) 2025 Expert Year-end Appreciation Meeting and Technology and Innovation Development Conference was held in Beijing. The conference brought together many top forces in the field of traditional Chinese medicine and authoritative experts in the field of artificial intelligence to witness Gushengtang's major cooperation and results release: Gushengtang's traditional Chinese medicine model cooperation agreement, launch of an integrated clinical research platform, Chinese medicine AI TCM brain release. In the same period, Gushengtang and Gaode Map reached a strategic cooperation and acquired 100% of the shares of Chinese traditional Chinese medicine in Singapore. The series of collaborations covered AI model R&D and clinical research, traffic matrix construction and overseas layout, showing Gushengtang's comprehensive plans to promote the modern development of traditional Chinese medicine, injecting the development of traditional Chinese medicine into four major sectors. Strong power.
Tu Zhiliang, founder and chairman of Gushengtang Traditional Chinese Medicine Group, said in his speech at the conference: “Promoting the modernization and internationalization of traditional Chinese medicine is the mission of the times in response to national policy calls, and it is also an inevitable choice for Gushengtang as an industry practitioner. We continue to invest in the development of large AI models and the development of overseas markets, not only in technological innovation and commercial layout, but its fundamental purpose is to expand the supply and service capabilities of high-quality traditional Chinese medicine resources.” He has drawn a clear blueprint for internationalization: he plans to expand his business to the Hong Kong and Malaysian markets in 2026, and then enter the European and American markets.
Chinese medicine master Wang Qingguo, Academician of the European Academy of Sciences and Executive Vice President of the Institute of Artificial Intelligence at Tsinghua University, Liu Baoyan, chief researcher at the Chinese Academy of Traditional Chinese Medicine and Chairman of the World Federation of Acupuncture and Moxibustion Societies, Tu Zhiliang, founder and chairman of Gushengtang Traditional Chinese Medicine Group, and nearly 1,000 guests representing industry experts attended the conference. More than 10 regions of Gushengtang simultaneously set up branch venue connections to witness the deep integration of traditional Chinese medicine with cutting-edge technology.
1. Join hands with four top research teams to create a new benchmark for AI models of traditional Chinese medicine
One of the highlights of this conference was that Gushengtang announced in-depth cooperation with four top research teams — Professor Sun Maosong's team from Tsinghua University, Professor Gu Xiaohong's team from Beijing University of Traditional Chinese Medicine, Professor Liu Baoyan's team from the Chinese Academy of Traditional Chinese Medical Sciences, and Professor Zhou Xuezhong's team from Beijing Jiaotong University to jointly develop major models and smart devices characteristic of traditional Chinese medicine.
The four top research teams are authoritative representatives in their respective fields, covering key fields such as AI, traditional Chinese medicine, interdisciplinary medical engineering, and clinical efficacy evaluation of traditional Chinese medicine, forming an interdisciplinary and comprehensive technical support system to enhance the clinical practicality and reliability of the AI model of traditional Chinese medicine from the root of the technology.
According to our understanding, there are five main aspects of this cooperation: First, building an AI model base that is more suited to the characteristics of traditional Chinese medicine diagnosis and treatment, and improving the clinical practicality and reliability of traditional Chinese medicine AI models and agents from the root of technology. Second, work with the Chinese Academy of Information and Communications Technology and other authorities to establish a scientific and rigorous AI evaluation system for traditional Chinese medicine, establish an industry professional ranking evaluation, and ensure impartial evaluation and continuous optimization of model performance. Third, build a “Chinese medicine AI split” auxiliary diagnosis and treatment system and traditional Chinese medicine AI application products to help patients with health management assistants. The former empowers primary doctors to improve diagnosis and treatment capabilities, while the latter optimizes patients' medical experience. Fourth, integrate data resources such as traditional Chinese medicine books, historical medical cases, classic prescriptions, and high-quality expert cases to contribute data support to industry model training and R&D. Fifth, it produces high-level academic results and publishes high-level papers in authoritative journals and conferences at home and abroad every year.
At the conference, Gushengtang also unveiled the second phase of the “Chinese Medicine AI Double” product, TCM Brain, which inherits the wisdom of famous doctors through AI technology, provides real-time clinical decision guidance for young doctors and accelerates the growth of young physicians. By connecting to the Gushengtang HIS system, the product realizes intelligent assistance for all aspects of diagnosis and treatment. Currently, internal trial operation has started in specialized specialties such as spleen and stomach, oncology, otolaryngology, etc., and dozens of young physicians have participated in the trial.
Professor Sun Maosong gave high praise to this cooperation. He said that Gushengtang's forward-looking strategic vision has carried out a systematic long-term layout in the field of intelligent traditional Chinese medicine. The release of Guoshengtang's AI variant shows the unique industry barriers built by Gushengtang under the “scene-data-technology” trinity model, and has explored a clear and viable path for the modern development of traditional Chinese medicine.
2. Launch an integrated clinical research platform to accelerate research and development of proprietary Chinese medicines
In order to accelerate the transformation of clinical research results, Gushengtang, together with authoritative research forces such as Professor Liu Baoyan's team from the Chinese Academy of Traditional Chinese Medical Sciences, Professor Zhou Xuezhong's team from Beijing Jiaotong University, and West China Hospital of Sichuan University officially launched an integrated clinical research platform project.
The platform will focus on the clinical evaluation problems of real-world data of traditional Chinese medicine and use artificial intelligence to build a full-chain innovation system from data governance and efficacy verification to application transformation.
At present, Gushengtang has registered a total of 16 in-hospital formulations. Among them, “Hair Care Hair Care Granules” have been successfully certified and marketed by the Singapore Health Sciences Authority (HSA), demonstrating the company's excellent R&D strength. With the advancement of integrated clinical research platforms, Gushengtang is expected to launch more innovative proprietary Chinese medicines with strong clinical efficacy, loved by ordinary people, and affordable, to benefit patients.
3. Build a traffic matrix to link traditional Chinese medicine to go overseas, broaden service boundaries and global reach
While consolidating the foundation of technology and scientific research, Gushengtang simultaneously promotes the construction of a traffic ecosystem and global layout, and broadens the boundaries of traditional Chinese medicine services through “internal and external training”.
At the conference, Gushengtang and Gaode Map signed a strategic cooperation agreement to deeply integrate traditional Chinese medicine diagnosis and treatment services with map navigation and local life scenarios to establish a closed loop of “travel - consumption - experience”, significantly improving the convenience of users to visit the store. This collaboration became a key layout for Goseido's panoramic traffic matrix.
Previously, Gushengtang had established in-depth cooperation with platforms such as Meituan, Douyin, and Xiaohongshu to form an online traffic matrix covering multiple dimensions such as local lifestyle services, social entertainment sharing, and vertical interest planting. This time, it has been connected to the Gaode Map navigation portal to further achieve seamless access to “where the demand is, where the service is”.
In terms of traditional Chinese medicine going overseas, Gushengtang adopted a “merger and acquisition+cooperation+self-construction” three-wheel drive strategy to accelerate globalization with Singapore as a bridgehead. At this conference, Gushengtang reached a strategic cooperation with Chinese Traditional Chinese Medicine in Singapore to wholly acquire 14 TCM clinics it controls. The brand was founded in 1996, has mature localization capabilities and a stable customer base, and stores cover core business districts and residential communities. With the implementation of the cooperation, Gushengtang will increase the number of traditional Chinese medicine diagnosis and treatment institutions in Singapore to 16, creating a significant synergy effect.
From AI big model development to scientific research transformation, from traffic ecosystem construction to overseas layout, the many cooperation and innovation results presented at this conference clearly outlined Gushengtang's full-dimensional development system of “AI empowers diagnosis and treatment, research-driven products, traffic link requirements, and overseas market expansion”. With the implementation of various cooperation results, Gushengtang is expected to further consolidate its leading position in the field of traditional Chinese medicine and inject new momentum into promoting the high-quality development of the traditional Chinese medicine industry.